SCHEMBL316645

SCHEMBL316645

Oc1cnccc1Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29947377 1.00 — —
Ammonia Solution, Strong SCHEMBL28048774 0.97 — —
SCHEMBL627795 0.79 — —
SCHEMBL30001725 0.79 — —
SCHEMBL8375145 0.77 LMNA (0.44) —
SCHEMBL2283975 0.75 — —
SCHEMBL1203743 0.75 — —
SCHEMBL7670567 0.74 — —
SCHEMBL22236422 0.72 RPS6KA3 (0.50) —
Bromide SCHEMBL20854689 0.72 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570631-B2 Substituted N-(4-(pyrimidin and pyridin-4-yl)benzylcarboxamides and its use for treating disorders responsive to inhibition of Btk BIOGEN MA INC. (US) 2026-03-10 — — US disclosed
EP-4688750-A1 SUBSTITUTED INDAZOLE PROPIONIC ACID DERIVATIVE COMPOUNDS AND USES THEREOF AS AMPK ACTIVATORS Pfizer Inc. (US) 2026-02-11 — — EP disclosed
US-20260035365-A1 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER BAYER AKTIENGESELLSCHAFT (DE) 2026-02-05 — — US disclosed
US-20260001898-A1 Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof ACCRO BIOSCIENCE HK LTD (HK) 2026-01-01 — — US disclosed
EP-4337648-B1 SUBSTITUTED HETEROCYCLIC COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2025-12-24 — — EP disclosed
EP-4628167-A2 SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT Alkermes, Inc. (US) 2025-10-08 — — EP disclosed
EP-4065585-B1 SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT ALKERMES INC (US) 2025-08-20 — — EP disclosed
US-20250236621-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN INC. 2025-07-24 — — US disclosed
WO-2025137541-A1 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2025-06-26 — — WO disclosed
EP-4565584-A1 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER Bayer Aktiengesellschaft (DE) 2025-06-11 — — EP disclosed
WO-2006100413-A2 NOVEL COMPOUNDS DERIVED FROM 5-THIOXYLOSE AND THERAPEUTIC USE THEREOF LABORATOIRES FOURNIER S.A. (FR) 2006-09-28 — — WO disclosed
WO-2006092731-A1 1, 2, 4-TRIAZOLE DERIVATIVES AND THEIR USE AS OXYTOCIN ANTAGONISTS PFIZER LIMTED (GB) 2006-09-08 — — WO disclosed
EP-0663912-B1 HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION ABBOTT LAB (US) 2001-12-12 — — EP disclosed
EP-1047690-A1 HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION Abbott Laboratories (US) 2000-11-02 — — EP disclosed
US-5948793-A 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release ABBOTT LABORATORIES (US) 1999-09-07 — — US disclosed
WO-1999032480-A1 HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION ABBOTT LABORATORIES (US) 1999-07-01 — — WO disclosed
US-5914328-A CONTROL DOPAMINE RELEASE, ACTIVATE CHOLINERGIC CHANNELS ABBOTT LABORATORIES (US) 1999-06-22 — — US disclosed
EP-0663912-A1 HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION ABBOTT LABORATORIES (US) 1995-07-26 — — EP disclosed
EP-0663912-A4 HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION. ABBOTT LAB (US) 1995-02-17 — — EP disclosed
WO-1994008992-A1 HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION ABBOTT LABORATORIES (US) 1994-04-28 — — WO disclosed
Send feedback